The anti-leukemic activity of the Flt3 inhibitor sorafenib, that was developed to target poor prognosis-ITD Flt3 AML cells, could be enhanced by metformin, thus inducing a strong decrease in the expression of several components of the mTOR pathway (93). This evidence concerns the gene FLT3 and acute myeloid leukemia.